Nothing Special   »   [go: up one dir, main page]

CO2017004596A2 - Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf - Google Patents

Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf

Info

Publication number
CO2017004596A2
CO2017004596A2 CONC2017/0004596A CO2017004596A CO2017004596A2 CO 2017004596 A2 CO2017004596 A2 CO 2017004596A2 CO 2017004596 A CO2017004596 A CO 2017004596A CO 2017004596 A2 CO2017004596 A2 CO 2017004596A2
Authority
CO
Colombia
Prior art keywords
high concentration
solution containing
vegf antibody
antibody
protein formulation
Prior art date
Application number
CONC2017/0004596A
Other languages
English (en)
Inventor
Huixiang Zhang
Charles Boring
Alok Kulshreshtha
Yuhong Zeng
Li Wan
Laman Alani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017004596(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2017004596A2 publication Critical patent/CO2017004596A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona anticuerpos anti-VEGF formulados como composiciones farmacéuticas acuosas de alta concentración, adecuadas para inyección, preferiblemente, una inyección intravitreal. Las composiciones farmacéuticas acuosas son útiles para la entrega de una alta concentración del ingrediente activo anticuerpo a un paciente sin niveles altos de agregación de anticuerpo y sin niveles altos de material particulado sub-visible. Una composición farmacéutica de la invención que comprende un anticuerpo que tiene una concentración de al menos 50mg/ml. Una composición farmacéutica acuosa de la invención que incluye un azúcar, un agente regulador de pH y un surfactante
CONC2017/0004596A 2014-11-07 2017-05-05 Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf CO2017004596A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059571 WO2016073915A1 (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Publications (1)

Publication Number Publication Date
CO2017004596A2 true CO2017004596A2 (es) 2017-08-31

Family

ID=54697654

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004596A CO2017004596A2 (es) 2014-11-07 2017-05-05 Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf

Country Status (24)

Country Link
US (5) US10035850B2 (es)
EP (2) EP3215122A1 (es)
JP (6) JP6667519B2 (es)
KR (4) KR102588846B1 (es)
CN (3) CN106999581A (es)
AU (6) AU2015342818B2 (es)
BR (2) BR112017008093A2 (es)
CA (2) CA2966758A1 (es)
CL (2) CL2017001115A1 (es)
CO (1) CO2017004596A2 (es)
EA (1) EA201790989A1 (es)
EC (1) ECSP17034829A (es)
GT (1) GT201700096A (es)
IL (5) IL251642B (es)
MX (3) MX2017005875A (es)
MY (2) MY193913A (es)
NZ (1) NZ730821A (es)
PE (1) PE20170780A1 (es)
PH (3) PH12021550147A1 (es)
RU (1) RU2722643C2 (es)
SG (3) SG11201702909QA (es)
TN (1) TN2017000128A1 (es)
TW (4) TWI806150B (es)
WO (2) WO2016073915A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2371865T (pt) 2006-04-07 2017-10-19 Aerpio Therapeutics Inc ANTICORPOS QUE SE LIGAM À FOSFATASE TIROSINA DE PROTEÍNAS HUMANA BETA (FTPH-ß) E SUAS UTILIZAÇÕES
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CN107090035A (zh) 2008-06-25 2017-08-25 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JP2014530244A (ja) 2011-10-13 2014-11-17 エアピオ セラピューティックス， インコーポレイテッド 血管漏出症候群および癌を治療する方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
KR20180054677A (ko) 2015-09-23 2018-05-24 에르피오 세러퓨틱스 인코포레이티드 Tie-2의 활성화제로 안내압을 치료하는 방법
UA126373C2 (uk) 2015-12-04 2022-09-28 Новартіс Аг Композиція і спосіб для імуноонкології
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
JP6975722B2 (ja) 2016-11-18 2021-12-01 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
MX2019011272A (es) 2017-03-22 2019-10-24 Novartis Ag Composiciones y metodos para inmunooncologia.
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN109562166B (zh) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
BR112020006434A2 (pt) 2017-10-06 2020-11-03 Prothena Biosciences Limited anticorpos anti-transtirretina
CN111433223B (zh) * 2017-11-29 2024-08-27 诺和诺德A/S（股份有限公司） 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
NZ767586A (en) 2018-03-02 2024-09-27 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
WO2019175727A1 (en) * 2018-03-16 2019-09-19 Novartis Ag Methods for treating ocular diseases
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NEW DUAL ANTAGONISTS OF VEGF AND ANGIOPOIETIN 2
EP4364724A3 (en) 2018-05-10 2024-08-07 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CA3115747A1 (en) * 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
PE20211865A1 (es) * 2018-10-29 2021-09-21 Hoffmann La Roche Formulacion de anticuerpos
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
KR20210106476A (ko) * 2018-12-18 2021-08-30 노파르티스 아게 고농도의 항-vegf 항체를 함유하는 단백질 용액 제형
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
TWI862583B (zh) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
EP3844169A4 (en) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKINS
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111217834B (zh) 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
WO2021233408A1 (zh) * 2020-05-21 2021-11-25 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
TW202313095A (zh) * 2021-05-17 2023-04-01 美商再生元醫藥公司 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2024056058A1 (zh) * 2022-09-16 2024-03-21 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI1802334T1 (sl) * 2004-10-21 2012-12-31 Genentech, Inc. Postopek za zdravljenje intraokularnih neovaskularnih bolezni
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007261536B2 (en) 2006-06-16 2012-02-16 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US20090175847A1 (en) 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CN107090035A (zh) 2008-06-25 2017-08-25 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
KR101678925B1 (ko) 2008-06-30 2016-11-24 에스바테크 - 어 노바티스 컴파니 엘엘씨 기능화 폴리펩티드
SG2014011340A (en) 2009-12-21 2014-07-30 Genentech Inc Antibody formulation
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
KR20210030510A (ko) * 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
SG194932A1 (en) * 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
AR088403A1 (es) * 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Anticuerpo de union a multiples antigenos estable
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP6774340B2 (ja) * 2014-06-17 2020-10-21 クリアサイド バイオメディカル，インコーポレイテッド 後眼部障害を処置するための方法およびデバイス
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
WO2019175727A1 (en) 2018-03-16 2019-09-19 Novartis Ag Methods for treating ocular diseases
KR20210106476A (ko) 2018-12-18 2021-08-30 노파르티스 아게 고농도의 항-vegf 항체를 함유하는 단백질 용액 제형

Also Published As

Publication number Publication date
MY183807A (en) 2021-03-16
IL251642B (en) 2021-02-28
BR112017008660A2 (pt) 2017-12-26
PH12017500844A1 (en) 2017-10-30
KR20170076781A (ko) 2017-07-04
AU2018274882A1 (en) 2018-12-20
PH12021550147A1 (en) 2023-01-23
RU2020114917A3 (es) 2022-01-17
SG10201913565RA (en) 2020-02-27
KR20230066649A (ko) 2023-05-16
EP3215122A1 (en) 2017-09-13
AU2015342818B2 (en) 2019-01-03
JP6667519B2 (ja) 2020-03-18
JP2025004075A (ja) 2025-01-14
CA2966758A1 (en) 2016-05-12
US20210340242A1 (en) 2021-11-04
MX2017005875A (es) 2017-06-26
TWI806150B (zh) 2023-06-21
CN107635580A (zh) 2018-01-26
AU2018278870B2 (en) 2020-05-28
TN2017000128A1 (en) 2018-10-19
AU2020220210A1 (en) 2020-10-01
GT201700096A (es) 2019-10-10
IL251696A0 (en) 2017-06-29
EA201790989A1 (ru) 2017-09-29
ECSP17034829A (es) 2019-02-28
RU2020114917A (ru) 2020-05-22
KR102588846B1 (ko) 2023-10-16
IL251642A0 (en) 2017-06-29
IL283561B (en) 2022-01-01
RU2017119647A3 (es) 2019-05-29
CL2017001117A1 (es) 2018-01-26
BR112017008093A2 (pt) 2018-03-13
EP3215123A1 (en) 2017-09-13
WO2016073915A1 (en) 2016-05-12
IL265497A (en) 2019-05-30
AU2020220210B2 (en) 2022-01-20
IL265497B (en) 2021-06-30
PH12017500844B1 (en) 2021-05-05
SG11201702954XA (en) 2017-05-30
JP2017534638A (ja) 2017-11-24
CN106999581A (zh) 2017-08-01
CN114081951A (zh) 2022-02-25
JP7080263B2 (ja) 2022-06-03
PH12017500843A1 (en) 2017-10-30
US11098110B2 (en) 2021-08-24
IL280087B (en) 2022-02-01
US20160130337A1 (en) 2016-05-12
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
RU2017119647A (ru) 2018-12-07
US12049495B2 (en) 2024-07-30
TW201625221A (zh) 2016-07-16
JP2020079242A (ja) 2020-05-28
US20200270336A1 (en) 2020-08-27
AU2020244614A1 (en) 2020-11-05
TW201625306A (zh) 2016-07-16
MX2021006768A (es) 2021-07-15
AU2018274882B2 (en) 2020-07-09
CL2017001115A1 (es) 2018-01-26
MX2017005874A (es) 2017-06-26
US10035850B2 (en) 2018-07-31
TWI738632B (zh) 2021-09-11
IL280087A (en) 2021-03-01
TWI761959B (zh) 2022-04-21
TW202146049A (zh) 2021-12-16
TW202103735A (zh) 2021-02-01
KR20240161204A (ko) 2024-11-12
RU2722643C2 (ru) 2020-06-02
JP2017538674A (ja) 2017-12-28
AU2015342815A1 (en) 2017-05-11
JP6753848B2 (ja) 2020-09-09
MY193913A (en) 2022-11-01
KR20170082526A (ko) 2017-07-14
NZ730821A (en) 2019-11-29
AU2020244614B2 (en) 2023-06-01
US20160340420A1 (en) 2016-11-24
AU2018278870A1 (en) 2019-01-03
PE20170780A1 (es) 2017-07-04
US20180298092A1 (en) 2018-10-18
TWI705827B (zh) 2020-10-01
WO2016073918A1 (en) 2016-05-12
JP2020193212A (ja) 2020-12-03
JP2022141923A (ja) 2022-09-29
KR102724014B1 (ko) 2024-10-31
CA2966646A1 (en) 2016-05-12
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
IL283561A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CO2017004596A2 (es) Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CO7111300A2 (es) Formulación de anticuerpos
AR107014A1 (es) Formulación farmacéutica acuosa
CO2019011463A2 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
CL2018003178A1 (es) Composición farmacéutica
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf